---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-040429"
form_type: "8-K"
ticker: null
cik: "0001840904"
company_name: "ATAI Life Sciences N.V."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:24:09.605914+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atai Beckley completes acquisition of Beckley Psytech, creating AtaiBeckley; issues ~105M shares

## Summary
- Consideration of ~105M new shares issued to Beckley Psytech shareholders, representing ~28% of combined company.
- Combined cash expected to fund operations into 2029, through first Phase 3 trial of BPL-003 for TRD.
- BPL-003 (mebufotenin benzoate nasal spray) is Phase 3-ready; End-of-Phase 2 FDA meeting scheduled, Phase 3 start Q2 2026.
- Board: Christian Angermayer (Chairman), Scott Braunstein (Vice Chairman), Cosmo Feilding Mellen, Robert Hershberg.
- Shareholders approved redomiciliation to Delaware; expected completion around year-end 2025.

## SEC filing metadata
- accession: 0001140361-25-040429
- form_type: 8-K
- cik: 0001840904
- company_name: ATAI Life Sciences N.V.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/ef20058318_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-040429
- JSON: https://secwatch.observer/filing/0001140361-25-040429.json
- Plain text: https://secwatch.observer/filing/0001140361-25-040429.txt

## Source-grounded claims
- claim_id: 368638c820dfb9f7be3b5a3394de87fda4729205
  claim: ATAI Life Sciences N.V. completed an acquisition involving shareholders of Beckley Psytech for 103,000,066 ordinary shares in atai’s capital (closed 2025-11-05).
  evidence_excerpt: Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840904/000114036125040429/0001140361-25-040429-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.